🔎 Trials Near Me

Beranda › Meduloblastoma › Distrik Columbia

Uji klinis Meduloblastoma di Distrik Columbia

7 studi untuk Meduloblastoma mencari peserta di lokasi di Distrik Columbia.

Kota di Distrik Columbia

Teks studi resmi (Bahasa Inggris)

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

  • Children's National Hospital, Washington D.C.
Menerima pesertaFase 1/2
Usia 1 hingga 25 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07346157

Digoxin Medulloblastoma Study

  • Children's National Medical Center, Washington D.C.
Menerima pesertaFase 2
12 Months – 30 Years · Semua jenis kelamin · Diperbarui 26 Agu 2026 · NCT06701812

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

  • Children's National Medical Center, Washington D.C.
Menerima pesertaFase 3
Usia 4 hingga 21 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05382338

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Children's National Medical Center, Washington D.C.
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma

  • Children's National Hospital, Washington D.C.
Menerima peserta
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05057702

Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma

  • Children's National Hospital, Washington D.C.
Menerima pesertaFase 1
Usia 4 hingga 30 · Semua jenis kelamin · Diperbarui 7 Agu 2026 · NCT06514898

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

  • Children's National Hospital, Washington D.C.
Menerima pesertaFase 1
Usia 1 hingga 30 · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06193759

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.